$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000101247724000017 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$50.03M	$41.50M
YoY Change	613.22%	2674.33%
Cost Of Revenue	$6.155M	$2.788M
YoY Change	5160.68%	7644.44%
Gross Profit	$43.87M	$38.72M
YoY Change	536.07%	2551.78%
Gross Profit Margin	87.7%	93.28%
Selling, General & Admin	$40.39M	$47.41M
YoY Change	3.16%	1.34%
% of Gross Profit	92.08%	122.45%
Research & Development	$3.803M	$4.051M
YoY Change	33.49%	-4.07%
% of Gross Profit	8.67%	10.46%
Depreciation & Amortization	$1.035M	$437.0K
YoY Change	75.42%	-27.29%
% of Gross Profit	2.36%	1.13%
Operating Expenses	$44.20M	$51.46M
YoY Change	5.21%	0.89%
Operating Profit	-$327.0K	-$12.74M
YoY Change	-99.07%	-74.28%
Interest Expense	-$2.820M	-$2.716M
YoY Change	42.42%	18.34%
% of Operating Profit
Other Income/Expense, Net	$610.0K	$1.126M
YoY Change	-32.22%	80.74%
Pretax Income	-$2.537M	-$14.33M
YoY Change	-92.99%	-77.73%
Income Tax	$88.00K	-$509.0K
% Of Pretax Income
Net Earnings	-$2.625M	-$13.82M
YoY Change	-92.76%	-78.55%
Net Earnings / Revenue	-5.25%	-33.3%
Basic Earnings Per Share	-$0.03	-$0.14
Diluted Earnings Per Share	-$0.03	-$0.14
COMMON SHARES
Basic Shares Outstanding	96.27M shares	96.12M shares
Diluted Shares Outstanding	96.30M shares	96.15M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.81M	$71.38M
YoY Change	-57.05%	-55.53%
Cash & Equivalents	$28.58M	$28.85M
Short-Term Investments	$37.23M	$42.54M
Other Short-Term Assets	$1.946M	$672.0K
YoY Change	149.81%	-89.6%
Inventory	$16.10M	$13.31M
Prepaid Expenses	$6.306M	$6.109M
Receivables	$37.10M	$33.38M
Other Receivables	$0.00	$927.0K
Total Short-Term Assets	$127.3M	$125.8M
YoY Change	-26.12%	-26.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$469.0K	$484.0K
YoY Change	-27.62%	-75.18%
Goodwill	$16.84M	$16.84M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.76M	$12.02M
YoY Change	15.88%	13.99%
Total Long-Term Assets	$31.00M	$31.74M
YoY Change	0.49%	6.71%
TOTAL ASSETS
Total Short-Term Assets	$127.3M	$125.8M
Total Long-Term Assets	$31.00M	$31.74M
Total Assets	$158.3M	$157.5M
YoY Change	-22.08%	-21.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.917M	$9.794M
YoY Change	-40.31%	-16.9%
Accrued Expenses	$33.91M	$33.71M
YoY Change	88.82%	81.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$42.78M	$44.61M
YoY Change	-20.85%	-13.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.154M	$5.819M
YoY Change	-11.41%	-7.37%
Total Long-Term Liabilities	$5.154M	$5.819M
YoY Change	-11.41%	-7.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.78M	$44.61M
Total Long-Term Liabilities	$5.154M	$5.819M
Total Liabilities	$83.59M	$87.23M
YoY Change	-10.07%	50.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$789.3M	-$786.7M
YoY Change	10.13%	15.61%
Common Stock	$887.8M	$881.2M
YoY Change	4.1%	3.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.66M	$70.29M
YoY Change
Total Liabilities & Shareholders Equity	$158.3M	$157.5M
YoY Change	-22.08%	-21.62%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$2.625M	-$13.82M
YoY Change	-92.76%	-78.55%
Depreciation, Depletion And Amortization	$1.035M	$437.0K
YoY Change	75.42%	-27.29%
Cash From Operating Activities	-$6.890M	-$18.19M
YoY Change	-81.97%	-43.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$4.930M	$10.55M
YoY Change	-49.8%	-111.36%
Cash From Investing Activities	$4.930M	$10.55M
YoY Change	-49.8%	-111.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.177M	723.0K
YoY Change	-96.14%	-99.21%
NET CHANGE
Cash From Operating Activities	-6.890M	-18.19M
Cash From Investing Activities	4.930M	10.55M
Cash From Financing Activities	1.177M	723.0K
Net Change In Cash	-783.0K	-6.913M
YoY Change	-138.01%	-79.29%
FREE CASH FLOW
Cash From Operating Activities	-$6.890M	-$18.19M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	584000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5389000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78384000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13822000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-95216000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1189000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2460000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13822000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1557000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4400000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-451000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-2127000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96151000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96151000	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13822000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-74000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-385000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-459000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14281000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28847000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42535000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33377000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	13313000	usd
CY2024Q2	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	927000	usd
CY2023Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	1322000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5286000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	134202000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	585000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2591000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	16836000	usd
CY2024Q2	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	252000	usd
CY2023Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	332000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12015000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10152000	usd
CY2024Q2	us-gaap	Assets Assets	157521000	usd
CY2023Q4	us-gaap	Assets Assets	164698000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	866000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	934000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9794000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11433000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33711000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24227000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	242000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	261000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	44613000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36855000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1308000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1690000	usd
CY2024Q2	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	35493000	usd
CY2023Q4	avdl	Royalty Financing Liability Noncurrent RoyaltyFinancingLiabilityNoncurrent	32760000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5819000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5654000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	87233000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	76959000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5194000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5194000	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	52000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96204000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89825000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89825000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	961000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	898000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	880202000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	855452000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-786660000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-745496000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24215000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23167000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	70288000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87739000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157521000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	164698000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	87739000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-27342000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-589000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9250000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3356000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13822000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-459000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	723000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5462000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	70288000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	315000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1522000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-38166000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-64432000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	83000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134151000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	102162000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1750000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7644000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	143192000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41164000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	978000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10851000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9166000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13129000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1208000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	42000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21274000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1775000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2264000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1439000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1638000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2470000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9484000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10246000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	549000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	255000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47890000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62256000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	207835000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	25618000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	175898000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	113460000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	31937000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87842000	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	17500000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4357000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4663000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1779000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13913000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125986000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-280000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2320000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23996000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31167000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73981000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28847000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49985000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1748000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4520000	usd
CY2023Q2	avdl	Orphan Drug Exclusivity Term OrphanDrugExclusivityTerm	P7Y
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	1
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified within the notes to the unaudited condensed consolidated financial statements to condense line items of the same nature to conform with the current year presentation.</span></div>
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	42320000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	215000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	42535000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	72990000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	954000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73944000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	709000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	1107000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	42535000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	42535000	usd
CY2024Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	2566000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	5291000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4819000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2037000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5928000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3052000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	13313000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10380000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Royalty Payment Percentage RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage	0.0375
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2023Q1	avdl	Royalty Financing Proceeds Maximum RoyaltyFinancingProceedsMaximum	75000000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-509000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.036
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-416000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.010
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-490000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6109000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4373000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	672000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	913000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6781000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5286000	usd
CY2024Q2	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	11876000	usd
CY2023Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	9905000	usd
CY2024Q2	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	139000	usd
CY2023Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	247000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12015000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10152000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	15674000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11961000	usd
CY2024Q2	avdl	Remaining Performance Obligation Reserve Current RemainingPerformanceObligationReserveCurrent	11152000	usd
CY2023Q4	avdl	Remaining Performance Obligation Reserve Current RemainingPerformanceObligationReserveCurrent	4044000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5328000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7492000	usd
CY2024Q2	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	1557000	usd
CY2023Q4	avdl	Royalty Financing Liability Current RoyaltyFinancingLiabilityCurrent	730000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33711000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24227000	usd
CY2024Q2	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	4985000	usd
CY2023Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5407000	usd
CY2024Q2	us-gaap	Guaranty Liabilities GuarantyLiabilities	834000	usd
CY2023Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	247000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5819000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5654000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-13822000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-64432000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41164000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-95216000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96151000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77246000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93922000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70603000	shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96151000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77246000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93922000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70603000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1140000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2212000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1032000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6813000	shares
CY2024Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001012477-24-000017-index-headers.html	Edgar Link	pending
0001012477-24-000017-index.html	Edgar Link	pending
0001012477-24-000017.txt	Edgar Link	pending
0001012477-24-000017-xbrl.zip	Edgar Link	pending
avdl-20240630.htm	Edgar Link	pending
avdl-20240630.xsd	Edgar Link	pending
exhibit311q22024.htm	Edgar Link	pending
exhibit312q22024.htm	Edgar Link	pending
exhibit321q22024.htm	Edgar Link	pending
exhibit322q22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
avdl-20240630_def.xml	Edgar Link	unprocessable
avdl-20240630_lab.xml	Edgar Link	unprocessable
avdl-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avdl-20240630_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avdl-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2024 Q3 Form 10-Q Financial Statement

#000101247724000017 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2024 Q3 Form 10-Q Financial Statement

#000101247724000017 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl